Form 4 for CLDX Celldex Therapeutics, Inc.
Accepted 2022-08-15 00:00:00 ET · period of report 2022-08-11 · accession 0001415889-22-008608 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-08-15 | 2022-08-11+ | CLDX | Martin Samuel Bates | SVP AND CFO | S - Sale+OE | $36.52 | -20.0K | 24.4K | -45% | -$730.4K |
| DM | 2022-08-15 | 2022-08-11+ | CLDX | Martin Samuel Bates | SVP AND CFO | M - OptEx | $4.75 | +20.0K | 26.8K | +293% | +$95.1K |
| DM | 2022-08-15 | 2022-08-11+ | CLDX | Martin Samuel Bates | SVP AND CFO | M - OptEx | $0.00 | -20.0K | 10.8K | -65% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-12 | S | D | 14,261 | $36.76 | 27,664 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.24 to $37.23 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| 2 | Common | Common Stock | 2022-08-12 | S | D | 1,221 | $34.62 | 24,378 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.31 to $34.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| 3 | Common | Common Stock | 2022-08-12 | M | A | 3,876 | $9.02 | 28,254 | D | — | — | |
| 4 | Common | Common Stock | 2022-08-12 | S | D | 2,065 | $35.38 | 25,599 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.82 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| 5 | Common | Common Stock | 2022-08-12 | M | A | 13,671 | $2.78 | 41,925 | D | — | — | |
| 6 | Common | Common Stock | 2022-08-11 | S | D | 2,453 | $37.04 | 24,378 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.26 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| 7 | Common | Common Stock | 2022-08-11 | M | A | 2,453 | $9.02 | 26,831 | D | — | — | |
| 8 | Derivative | Incentive Stock Option (Right to Buy) | 2022-08-11 | M | D | 2,453 | $0.00 | 7,077 | D | $9.02 · — to 2028-06-13 | 2,453 Common Stock | (F5) As of June 13, 2022, the option is fully vested. |
| 9 | Derivative | Incentive Stock Option (Right to Buy) | 2022-08-12 | M | D | 3,876 | $0.00 | 3,201 | D | $9.02 · — to 2028-06-13 | 3,876 Common Stock | (F5) As of June 13, 2022, the option is fully vested. |
| 10 | Derivative | Incentive Stock Option (Right to Buy) | 2022-08-12 | M | D | 13,671 | $0.00 | 10,750 | D | $2.78 · — to 2029-06-19 | 13,671 Common Stock | (F6) 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |